hVIVO (LON:HVO) Trading Up 8.4% – What’s Next?

hVIVO plc (LON:HVO) shot up 8.4% during trading on Thursday . The stock traded as high as GBX 7.10 and last traded at GBX 7.10. 5,770,304 shares were traded during mid-day trading, an increase of 68% from the average session volume of 3,426,144 shares. The stock had previously closed at GBX 6.55.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HVO. Peel Hunt reaffirmed an “add” rating and set a GBX 10 target price on shares of hVIVO in a research note on Thursday, November 20th. Shore Capital lowered their price objective on shares of hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of GBX 17.50.

hVIVO Price Performance

The firm’s fifty day simple moving average is GBX 6.25 and its 200-day simple moving average is GBX 8.65. The firm has a market capitalization of £49.48 million, a PE ratio of 9.35 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.

hVIVO (LON:HVO) last posted its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, research analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other hVIVO news, insider Yamin Mo’ Khan acquired 3,310,405 shares of hVIVO stock in a transaction that occurred on Monday, December 15th. The stock was bought at an average cost of GBX 6 per share, for a total transaction of £198,624.30. Also, insider Stephen Pinkerton bought 520,000 shares of the stock in a transaction on Monday, December 15th. The shares were bought at an average price of GBX 6 per share, for a total transaction of £31,200. 4.43% of the stock is currently owned by company insiders.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.